The US Food and Drug Administration (FDA) has accepted BioCryst Pharmaceuticals’ new drug application (NDA) for Orladeyo ...

The NDA was based on positive interim data from the APEX-P clinical trial, which is the largest trial evaluating a ...

The FDA has accepted BioCryst’s new drug application for Orladeyo in pediatric patients and set a target action date of ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) ...

BioCryst on Wednesday said an FDA green light would make Orladeyo the first targeted oral prophylactic therapy for children under the age of 12 with hereditary angioedema, a genetic disorder ...

FDA grants Priority Review of application, with PDUFA target action date of September 12, 2025– –ORLADEYO would be the first ...

Shares of Astria Therapeutics climbed after the biopharmaceutical company provided an update on its in-development therapies and reported first-quarter results. The stock rose 9%, to $4.25, in ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

Expansion of potential treatment applications of deucrictibant in people living with bradykinin-mediated angioedemaZUG, Switzerland, May 12, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a ...

We recently published a list of Billionaire Glenn Russell Dubin’s 10 Stock Picks with Huge Upside Potential. In this article, ...

A newly developed Naples Pediatric Food Allergy grading scale, incorporating clinical history and examination, shows promise in streamlining the diagnosis of food allergies in children, potentially ...